Navigation Links
Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
Date:4/10/2012

BEER-SHEVA, ISRAEL, April 10, 2012 BGN Technologies, the technology transfer company for Ben-Gurion University of the Negev (BGU), has signed a licensing agreement for its V-Smart drug delivery technology with Lauren Sciences LLC, a privately held biotechnology company in New York.

Lauren Sciences will develop the technology as a platform for treating a variety of diseases that affect the central nervous system (CNS), including Parkinson's, Alzheimer's, Amyotrophic Lateral Sclerosis (ALS), as well as brain malignancies.

V-Smart technology is based on nanovesicles made of proprietary building blocks that provide high stability, large encapsulation capacity, targeting to specific cells and tissues, a controlled release mechanism, and passage through biological barriers, including the blood brain barrier (BBB). The V-SmartTM technology pinpoints where the drug will be released in the brain, increasing efficacy and reducing adverse effects.

It was developed by BGU researchers Dr. Sarina Grinberg of the Department of Chemistry, Dr. Charles Linder of the Department of Biotechnology and Department of Clinical Biochemistry Prof. Eliahu Heldman, who also serves as Lauren Science's chief scientific officer. Lauren Sciences will continue to conduct development activities at BGU.

"Our pre-clinical studies demonstrate that novel, nano-sized V-Smart vesicles encapsulate small molecules, peptides, proteins and nucleic acids, cross the BBB and release their encapsulated contents in the brain," said Prof. Heldman. "Our goal is to target, protect and restore dopaminergic neurons (nerve cells) in the brain that deteriorate during the course of Parkinson's disease. The success of this project should improve Parkinson's patients' lives."

The BBB is permeable for small molecules; however, an active drug delivery transport system is required for other substances. There is currently an unmet need and a great medical challenge for a safe, effective and reliable drug delivery transport system to deliver viable chemotherapeutic agents to the brain of patients with brain cancer or other CNS related clinical states.

The V-Smart platform is protected by several worldwide patents filed by BGN Technologies. Lauren Sciences was recently awarded a grant from the Michael J. Fox Foundation to develop a V-Smart therapeutic for Parkinson's disease.


'/>"/>

Contact: Andrew Lavin
andrewlavin@alavin.com
516-944-4486
American Associates, Ben-Gurion University of the Negev
Source:Eurekalert

Related biology news :

1. Ben-Gurion University of the Negev researchers help find that hypnosis can induce synesthesia
2. Ben-Gurion University of the Negev to host
3. Ben-Gurion University of the Negev researchers develop new reversible, green window technology
4. Ben-Gurion University engineers develop technique to help combat nuclear proliferation
5. Ben-Gurion University of the Negev signs collaborative contract with Bayer CropScience
6. Ben-Gurion University research and technology used in new solar energy farm
7. Ben-Gurion U. researchers reveal connection between cancer and human evolution
8. 1 in 6 health workers wont report in flu pandemic -- study by Ben-Gurion U. researchers
9. Ben-Gurion U. developing new computer techniques to analyze historic Hebrew and Arabic documents
10. Ben-Gurion University of the Negev technology being developed for use in Jordan desalination plant
11. Ben-Gurion University Alzheimers researcher demonstrates specific immune response to vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply for any ... So which eye do you rinse first if a dangerous substance enters both eyes? It’s ... Wash with its unique dual eye piece. , “Whether its dirt and debris, or ...
(Date:10/11/2017)... the Netherlands and LAGUNA HILLS, Calif. ... The Institute of Cancer Research, London ... use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients ... trial known as MUK nine . The University of ... trial, which is partly funded by Myeloma UK, and ICR ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking events company, ... today. The bold new look is part of a transformation to increase awareness, ... significant growth period. , It will also expand its service offering from its signature ...
(Date:10/10/2017)... 2017 International research firm Parks Associates announced today ... the TMA 2017 Annual Meeting , October 11 in ... home security market and how smart safety and security products impact the ... Parks Associates: Smart Home Devices: ... "The residential security market has experienced ...
Breaking Biology Technology: